Latest Regulatory Milestones News

Rua Gold’s Auld Creek Project has qualified for New Zealand’s new Fast-Track Approvals Act 2024, promising a faster permitting timeline and reduced regulatory risk as the company advances toward mine development.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

Connected Minerals has secured shareholder and regulatory approvals to acquire Frontier Group, gaining an 80% stake in Angola’s Bailundo Carbonatite Project with expanded mineral rights including niobium and rare earths. Completion is imminent as exploration activities ramp up.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Australian Silica Quartz Group (ASQ) finalises its acquisition of Australian Kaolin, securing a 47Mt kaolin resource and mining approval for a 250,000 tonne per annum operation. The company progresses kaolin beneficiation in China, explores high purity quartz projects, and advances gold targets at Koolyanobbing, supported by a $1.33m cash position.

Parkway Corporate delivered a record $7.25 million quarterly revenue and $0.54 million EBITDA, powered by a major water infrastructure contract. The company progressed key approvals for its Queensland Brine Management Complex and struck a strategic collaboration with Hitachi to develop advanced brine concentration technology.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.

Vault Minerals delivered on FY26 gold production guidance with strong quarterly output and cash flow, while progressing key projects and announcing a merger with Genesis Minerals to form a top 20 global gold producer.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.